Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by P. Armand
Nivolumab Plus Doxorubicin, Vinblastine and Dacarbazine for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma: Checkmate 205 Cohort D 2-Year Follow-Up
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 Keynote-087 Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow-Up of the Phase 2 Checkmate 205 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
REAL-WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS (PTS) TREATED WITH ANTI-PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Investigating Safety and Preliminary Efficacy of Afm13 Plus Pembrolizumab in Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
DAFS Study of Intermediate-Range Order in Ν-GeO2and Ν-GeSe2
Acta Crystallographica Section A Foundations of Crystallography
